Rapport Therapeutics Research Development Over Time
| RAPP Stock | 27.09 1.54 6.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rapport Therapeutics Performance and Rapport Therapeutics Correlation. Can Pharmaceuticals industry sustain growth momentum? Does Rapport have expansion opportunities? Factors like these will boost the valuation of Rapport Therapeutics. Anticipated expansion of Rapport directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Rapport Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Rapport Therapeutics is measured differently than its book value, which is the value of Rapport that is recorded on the company's balance sheet. Investors also form their own opinion of Rapport Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rapport Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Rapport Therapeutics' market value can be influenced by many factors that don't directly affect Rapport Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rapport Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rapport Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rapport Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Research Development Analysis
Compare Rapport Therapeutics and related stocks such as Nurix Therapeutics, Kodiak Sciences, and Phathom Pharmaceuticals Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRIX | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 45 M | 66.5 M | 116.4 M | 184.5 M | 189.1 M | 221.6 M | 308.2 M | 354.4 M | 372.1 M |
| KOD | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 22 M | 18.8 M | 37.5 M | 107.4 M | 217.3 M | 267.6 M | 206.3 M | 126.1 M | 145 M | 124.3 M |
| PHAT | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 99.3 M | 98.1 M | 72.3 M | 71.4 M | 49.9 M | 34.1 M | 30.7 M | 48.6 M |
| XNCR | 12.7 M | 12.7 M | 12.7 M | 17 M | 18.5 M | 34.1 M | 51.9 M | 71.8 M | 97.5 M | 118.6 M | 169.8 M | 192.5 M | 199.6 M | 253.6 M | 227.7 M | 261.8 M | 274.9 M |
| BBOT | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 73.1 M | 84.1 M | 71.2 M |
| ANAB | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.6 M | 17.3 M | 22.6 M | 30.9 M | 56.3 M | 99.3 M | 80 M | 98.5 M | 88.8 M | 139.6 M | 163.8 M | 188.4 M | 197.8 M |
| URGN | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 4 M | 10.5 M | 10.3 M | 18.7 M | 36.9 M | 49.3 M | 47.3 M | 47.6 M | 52.9 M | 45.6 M | 57.1 M | 65.7 M | 35.1 M |
| OCS | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.6 M | 22.2 M | 29.2 M | 52.1 M | 59.9 M | 62.9 M |
| SEPN | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 36 M | 65.3 M | 75.1 M | 45.2 M |
Rapport Therapeutics and related stocks such as Nurix Therapeutics, Kodiak Sciences, and Phathom Pharmaceuticals Research Development description
My Equities
My Current Equities and Potential Positions
| Rapport Therapeutics Common | RAPP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1325 Boylston Street, |
| Exchange | NASDAQ Exchange |
null 27.09
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.